Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
04 Outubro 2024 - 6:08PM
Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the
"Company"), a leader in medical aesthetics, today announced the
commencement of an offer to exchange up to 15,000,000 shares of its
currently issued and outstanding common stock, par value $0.0001
per share (the “Common Stock”) for up to 15,000,000 shares of the
Company’s newly issued Series B Preferred Stock (“Series B
Preferred Stock”), with each share of Common Stock being
exchangeable in for one share of Series B Preferred Stock. A
stockholder who desires to tender Common Stock in this offering
must tender all of such stockholder’s Common Stock. The exchange
offer will expire at the end of the day, 5:00 P.M., New York City
Time, on November 5, 2024, unless extended or withdrawn.
The exchange offer will be upon the terms and
subject to the conditions set forth in the Offer to Exchange, dated
October 4, 2024 (as amended and supplemented from time to time, the
“Offer to Exchange”) and the related Offer materials (as amended
and supplemented from time to time, the “Offer Documents”). The
terms of the exchange offer set forth in this press release are
just a summary and are qualified in their entirety by the Offer to
Exchange and Schedule TO filed with the Securities and Exchange
Commission on October 4, 2024.
About Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical
aesthetics and biopharmaceutical drug development, focusing on
innovations for skin aesthetics and treatments tied to obesity and
metabolic health. The Company operates a diverse portfolio of three
wholly owned subsidiaries across the medical aesthetics and
biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences
Inc., and Elevai Research Inc. For more information please
visit www.elevailabs.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
“believes,” “expects,” “plans,” “potential,” “would” and “future”
or similar expressions such as “look forward” are intended to
identify forward-looking statements. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based only on our current
beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy, activities of
regulators and future regulations and other future conditions.
Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results.
Therefore, you should not rely on any of these forward-looking
statements. These and other risks are described more fully in
Elevai’s filings with the Securities and Exchange Commission
(“SEC”), including the “Risk Factors” section of the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the SEC on March 29, 2024, and its other documents
subsequently filed with or furnished to the SEC. Investors and
security holders are urged to read these documents free of charge
on the SEC’s web site at www.sec.gov. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Except to the extent required by law,
the Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
IR
Contact:IR@ElevaiLabs.com
Elevai Labs (NASDAQ:ELAB)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Elevai Labs (NASDAQ:ELAB)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024